The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who currently are on a stable dose of metformin.

Inclusion Criteria:

• Diagnosis of type 2 diabetes
• Hb1AC >7%-11% inclusive
• Male and females 18-70; females must be post-menopausal
• On a stable dose of metformin hydrochloride

Exclusion Criteria:

• Medical history of stroke, unstable angina, heart attack within one year of enrollment, and alcohol dependency or recent drug abuse.
• Women of childbearing potential, pregnant or nursing
• Evidence of diabetic complications with significant end-organ damage